Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR Therapeutics nabs CMO from Sanofi

→ Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether.

Clozel will retire as CEO on June 13, and Idorsia has tapped his longtime lieutenant André Muller to replace him. The 69-year-old Clozel will now stand for election as chairman, while Mathieu Simon moves into the vice chairman post.

The changes on the board don’t stop there. Jörn Aldag, Felix Ehrat and Peter Kellogg are stepping down, and Idorsia has nominated ex-Galapagos president Bart Filius.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

For patients with NF2-related schwannomatosis and progressive tumors, the ALK inhibitor brigatinib (Alunbrig) was associated with radiographic response for multiple tumor types, as well as

June 22, 2024

The Biggest Psychedelic News This Week: November 6 – 10 | Psychedelic Spotlight

As researchers investigate the potential of psilocybin in cancer patients and LSD as treatment for ADHD, the psychedelic ecosystem witnesses more acquisitions, patents, and decriminalization

November 10, 2023

End of internet subsidies for low-income households threatens telehealth access

For Cindy Westman, $30 buys a week’s worth of gas to drive to medical appointments and run errands.

April 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.